GLP-1 Receptor Agonist (Non-peptide, Oral)
Investigational

Orforglipron

Pending FDA approval

Manufactured by Eli Lilly · Oral tablet

Avg Weight Loss

~14

Dosing

Once daily

Brand Cost

Pricing not yet established; expected to be significantly lower than injectable GLP-1s due to simpler manufacturing

Compounded

Non-peptide molecule may be harder to compound

How It Works

Orforglipron is a first-in-class oral non-peptide GLP-1 receptor agonist. Unlike oral semaglutide (Rybelsus), which is a peptide requiring absorption enhancers and fasting, orforglipron is a small molecule that activates GLP-1 receptors with high potency. It stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite — the same mechanisms as injectable GLP-1 agents but in a more convenient oral form without fasting requirements.

Pending FDA approval (Weight Management / Type 2 Diabetes)

Dosing & Titration

Orforglipron

3mg 12mg 24mg 36mg 45mg

Titration Protocol

Phase 3 protocol: Start at 3mg daily, increase every 4 weeks through 6mg, 12mg, 24mg, 36mg to maintenance dose of 45mg daily. Total titration period approximately 20 weeks.

Common Side Effects

Common Nausea Common Vomiting Common Diarrhea Common Decreased appetite Common Dyspepsia Common Constipation

Serious Risks

GI side effects (most common reason for discontinuation in Phase 2)

Pancreatitis (theoretical class risk)

Thyroid C-cell tumors (theoretical class risk, being evaluated)

Full safety profile still under investigation

Cost Comparison

Brand Name

Pricing not yet established; expected to be significantly lower than injectable GLP-1s due to simpler manufacturing

per month

Compounded

Non-peptide molecule may be harder to compound

per month

Pharmacy Options

Not yet available

Insurance Coverage

Not yet applicable. Oral formulation expected to improve access and potentially lower costs vs injectables.

Pros & Cons

Advantages

  • Oral tablet — no injections needed
  • No fasting requirement (unlike oral semaglutide/Rybelsus)
  • Small molecule — simpler, cheaper manufacturing than peptides
  • Room-temperature stable (no cold chain)
  • Could dramatically expand GLP-1 access and lower costs
  • Potentially resistant to compounding competition

Disadvantages

  • Not yet FDA approved
  • GI side effect rates similar to injectable GLP-1s
  • Daily dosing (vs weekly injection)
  • Weight loss may be less than tirzepatide at current doses
  • Limited long-term data
  • Higher discontinuation rates in trials vs injectable GLP-1s

Clinical Evidence

Clinical Trial Programs

ACHIEVE program: ACHIEVE-1 (obesity/overweight), ACHIEVE-2 (Type 2 Diabetes), ACHIEVE-3 (obesity with Type 2 Diabetes), ACHIEVE-4 (cardiovascular outcomes). Phase 2 results published in NEJM (2023).

phase2Obesity

14.7% body weight reduction at 45mg over 36 weeks vs 2.3% placebo

phase2Diabetes

2.1% A1C reduction at 45mg over 26 weeks vs 0.4% placebo

Contraindications

  • Not yet approved — contraindications will be determined through regulatory review
  • Likely to include MTC/MEN 2 history (consistent with GLP-1 class)

Find providers offering Orforglipron near you

Compare pricing, pharmacy sourcing, and clinical oversight across verified providers prescribing Pending FDA approval.

Compare Providers → Search by Location

Get weekly GLP-1 medication updates

New research, pricing changes, and provider comparisons — delivered to your inbox.

No spam. Unsubscribe anytime.

Compare all GLP-1 medications

See how Orforglipron stacks up against other GLP-1 options. Compare efficacy, cost, side effects, and dosing schedules side by side.

View All Medications →